BridgeMD
Pharmacokinetics study of Cefazolin in haemodialysis
EU CTIS ID: 2023-506734-73-00
What this study is testing
Description of the pharmacokinetics of cefazolin in chronic haemodialysis patients with infections, as part of routine care.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subjects aged 18 years or over
- On chronic intermittent dialysis
- With a stated indication for initiation of cefazolin either : 1/ For probabilistic treatment of a clinical presentation suggestive of SAMS infection 2/ For treatment of Gram-positive cocci bacteremia
- With the possibility of taking peripheral blood samples or blood samples from the dialysis machine until the next dialysis session at 48 hours
- Covered by or entitled to social security
- Signed informed consent form
You likely can't join if
- Pregnant or breastfeeding woman
- Dialysis lasting less than 3 hours, which most often corresponds to "acute" dialysis or the start of chronic dialysis which fundamentally changes the elimination profile
- Allergy to cephalosporin and penicillin antibiotics (5-10% risk of cross-reactivity)
- Non-anuric subjects with inhibitors of tubular creatinine secretion: Curative-dose trimethoprim, Cimetidine, Ritonavir, Rilpivirine, Dolutegravir, Cobicistat
- Patient following any measures of legal presentation
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.